Anixa Biosciences (ANIX) announced that the Chinese National Intellectual Property Administration, or CNIPA, has issued Patent Number ZL2020800215666, covering key aspects of the Company’s breast cancer vaccine technology. Anixa’s breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to the prevention and treatment of breast cancer. Anixa’s vaccine is based on immunizing against human alpha-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This “retired” protein vaccine strategy aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue. The vaccine was invented at Cleveland Clinic, and this patent-along with others related to this technology-has been exclusively licensed to Anixa Biosciences. A Phase 1 clinical trial of Anixa’s breast cancer vaccine has been recently completed and Cleveland Clinic will present full clinical results at the San Antonio Breast Cancer Symposium on December 11, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
- Anixa Biosciences completes patient visit in breast cancer vaccine trial
- Anixa announces final results from Phase 1 trial of breast cancer vaccine
- Anixa Biosciences: Promising Clinical Progress and Financial Stability Underpin Buy Rating
- Anixa Biosciences files $200M mixed securities shelf
- Promising Advancements and Strategic Positioning Propel Anixa Biosciences to a Buy Rating